ILMN

IlluminaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$155.00

-4.6% vs current

Most likely

Base case

45%

Probability

Target price

$136.00

-16.3% vs current

B-

Bear case

25%

Probability

Target price

$115.00

-29.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

Tone improved after the April 30, 2026 print because results beat expectations, guidance was raised, and secondary coverage described an immediate positive stock reaction of roughly 5% after hours. By the May 1, 2026 anchor close, shares were near the packet's median target, which argues the market credited the better quarter quickly. Headline buzz is elevated by earnings, but delayed analyst-revision coverage is still thin in the packet, and the corrected direct-peer lens shows competitive intensity in sequencing, spatial, and clinical workflows. This remains a cautious positive follow-up rather than a high-conviction upgrade.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-05-30catalystQ1 beat, raised FY2026 guide, and expanded buyback capacityHigh impact

Illumina's April 30 earnings release showed Q1 2026 revenue of $1.09B, non-GAAP EPS of $1.15, and higher FY2026 revenue, margin, and EPS guidance; the same 8-K also disclosed a new $1.5B repurchase authorization on top of roughly $314M remaining under the 2024 program [#8-K-2026-04-30].

2026-06-30event1H26 spatial transcriptomics launch remains a watch itemMedium impact

In its February 5, 2026 Q4/FY2025 company earnings materials, management said it remained on track to introduce its spatial transcriptomics solution in the first half of 2026, making launch timing and customer uptake an important next proof-point for the multiomics strategy [#PR-2026-02-05].

2026-09-30catalystNovaSeq X and software roadmap can support higher-value clinical and multiomic adoptionHigh impact

Company press releases highlighted an 18-month NovaSeq X upgrade roadmap with higher output, faster runs, and improved quality, while DRAGEN v4.5 added support for TruPath Genome and expanded oncology and rare-disease workflows; sustained adoption would reinforce the post-earnings guide raise but still needs field conversion and execution [#PR-2026-02-23] [#PR-2026-04-16].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology